Stockscreener 앱 받기
2.92
0.00%
0.00
시간 외 거래:
2.90
-0.02
-0.68%
Acumen Pharmaceuticals Inc 주식(ABOS)의 최신 뉴스
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - The Manila Times
Alzheimer's drug developer Acumen sets March 26 results webcast - Stock Titan
Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference - MarketBeat
RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan
Acumen Pharmaceuticals at Stifel Forum: Strategic Insights on Alzheimer’s Drug - Investing.com Canada
ABOS: Phase II Alzheimer's trial for sabirnetug targets late 2026 data, with EBD clinical entry by 2027 - TradingView
Acumen Pharmaceuticals, Inc. unveils novel antibodies targeting amyloid beta oligomers at ADPD2026 - Traders Union
RA Capital boosts Acumen (ABOS) ownership to 29.5% after $20M PIPE buy - Stock Titan
Acumen Unveils Enhanced Brain Delivery Technology and Latest Alzheimer's Research Findings at International AD/PD Conference - citybiz
Private placement at Acumen to advance EBD program - BioWorld MedTech
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $8.00 - MarketBeat
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget
Mouse study boosts brain delivery of Acumen’s Alzheimer’s antibody - Stock Titan
Acumen Raises Capital to Advance Enhanced Brain Delivery - The Globe and Mail
Dow Update: Whats Acumen Pharmaceuticals Incs historical return2026 Short Interest & Entry and Exit Point Strategies - baoquankhu1.vn
Institution Moves: Is Acumen Pharmaceuticals Inc a strong candidate for buy and hold2026 Macro Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Acumen Pharmaceuticals Raises $35.75 Million to Advance Enhanced Brain Delivery Alzheimer’s Therapy with Strong Preclinical Results 1 - Minichart
Acumen secures funding to advance enhanced brain delivery program - MSN
Acumen Pharmaceuticals, Inc. announced that it has received $35.749992 million in funding from RA Capital Management, L.P., ADAR1 Capital Management, LLC, Sands Capital Alternatives, LLC and other investors - marketscreener.com
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio - Bitget
Acumen Pharmaceuticals Raises $35.75 Million in Private Placement to Fund EBD Program - TradingView
Acumen Pharmaceuticals (NASDAQ: ABOS) secures $35.75M to advance EBD Alzheimer’s program - Stock Titan
Acumen Pharmaceuticals Announces $35.75 Million Private Placement To Advance Potential Best-In-Class Molecules From Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio - TradingView
Alzheimer’s brain drug: Acumen secures $35.75M after 40x uptake - Stock Titan
ABOS SEC FilingsAcumen Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Team members drive company mission, Acumen Pharmaceuticals, Inc. asserts - Traders Union
Acumen Pharma chief legal officer sells $6813 in stock By Investing.com - Investing.com Canada
Acumen (NASDAQ: ABOS) legal chief sells 2,090 shares after option exercise - Stock Titan
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Bitget
Alzheimer's therapeutics developer joins Stifel 2026 virtual CNS forum - Stock Titan
Stock Market Recap: What is the earnings history of Acumen Pharmaceuticals Inc2026 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Highs Report: Is Acumen Pharmaceuticals Inc a turnaround story2025 Fundamental Recap & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Spikes: What is the earnings history of Acumen Pharmaceuticals Inc2025 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acumen Pharmaceuticals (NASDAQ: ABOS) files Form 144 for insider sale - Stock Titan
Acumen Pharmaceuticals to Highlight New Alzheimer’s Research Progress at AD/PD™ 2026 - citybiz
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.80 Consensus Price Target from Analysts - Defense World
Acumen Pharma chief legal officer Meisner sells $28k in shares - Investing.com Australia
Acumen (NASDAQ: ABOS) CLO exercises options and sells 9,406 shares - Stock Titan
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 - mx.advfn.com
Acumen Pharmaceuticals to showcase advances in Alzheimer's treatment at international conference on Alzheimer's and Parkinson's diseases 2026 - marketscreener.com
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget
Acumen Pharmaceuticals To Showcase Advances In Alzheimer's Treatment At International Conference On Alzheimer’S And Parkinson’S Diseases 2026 - TradingView
New Alzheimer’s treatment data explores better delivery to the brain - Stock Titan
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Acumen Pharmaceuticals (ABOS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Acumen Pharmaceuticals (NASDAQ: ABOS) insider sells 9,406 shares - Stock Titan
ABOS Should I Buy - Intellectia AI
Profit Review: Can Acumen Pharmaceuticals Inc reach resistance levels soonTrend Reversal & Daily Chart Pattern Signals - baoquankhu1.vn
ABOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen - MarketBeat
Does Acumen Pharmaceuticals Inc. stock have upside surprise potentialJuly 2025 Spike Watch & Safe Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Market Trends: How is BlackSky Technology Inc Equity Warrant managing supply chain issuesJuly 2025 Recap & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Growth in Short Interest - Defense World
ABOS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will Acumen Pharmaceuticals Inc. stock reach Wall Street targetsWeekly Trend Report & Daily Risk Controlled Trade Plans - mfd.ru
Decliners Report: Is Acumen Pharmaceuticals Inc a cyclical or defensive stockJuly 2025 Summary & Long-Term Growth Plans - baoquankhu1.vn
ABOS PE Ratio & Valuation, Is ABOS Overvalued - Intellectia AI
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Increase in Short Interest - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):